Cleared Abbreviated

VISTA SCIENTIFIC BARIUM SULFATE, MODEL 3001-1 (K024359) - FDA 510(k) Clearance

Class II Neurology device cleared through the Abbreviated 510(k) pathway - typically does not require clinical trials.

K024359 · Vista Scientific, LLC · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2003
Decision
221d
Days
Class 2
Risk

K024359 is an FDA 510(k) clearance for the VISTA SCIENTIFIC BARIUM SULFATE, MODEL 3001-1. Classified as Accessory, Barium Sulfate, Methyl Methacrylate For Cranioplasty (product code MYU), Class II - Special Controls.

Submitted by Vista Scientific, LLC (Niwot, US). The FDA issued a Cleared decision on August 8, 2003 after a review of 221 days - an extended review cycle.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.5300 - the FDA neurology device framework. The Abbreviated 510(k) pathway was used, relying on FDA-recognized standards to demonstrate substantial equivalence.

Device pattern: Standards-based predicate clearance. Standards-verified equivalence. The Abbreviated pathway signals strong alignment with FDA-recognized performance standards - typically associated with lower review burden and faster clearance cycles.

View all Vista Scientific, LLC devices

Submission Details

510(k) Number K024359 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 30, 2002
Decision Date August 08, 2003
Days to Decision 221 days
Submission Type Abbreviated
Review Panel Neurology (NE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
73d slower than avg
Panel avg: 148d · This submission: 221d
Pathway characteristics
Standards-based clearance path.

Device Classification

Product Code MYU Accessory, Barium Sulfate, Methyl Methacrylate For Cranioplasty
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.5300
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.